A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer [0.03%]
血管内皮生长因子受体酪氨酸激酶抑制剂、哺乳动物雷帕霉素靶点抑制剂和程序性死亡1抑制剂治疗转移性肾细胞癌的经济评估系统评价
Panagiotis Petrou
Panagiotis Petrou
Introduction: The therapeutic categories of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors have transformed the treat...
Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology [0.03%]
系统评价和基准测试在肿瘤学中的经调整的无症状或不良反应质量时间（Q-TWiST）
Caitlyn T Solem,Youngmin Kwon,Ruchit M Shah et al.
Caitlyn T Solem et al.
Introduction: The Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) has been used to evaluate the clinical benefits and risks of oncology treatments. However, limited information is available to interpret and c...
What are the images used to diagnose and assess suspected strokes?: A systematic literature review of care in four European countries [0.03%]
欧洲四国用于诊断和评估疑似卒中的影像检查：一项系统文献回顾
Anne-Claire Peultier,Ken Redekop,Emmanuel Coche et al.
Anne-Claire Peultier et al.
Introduction: The cost-effectiveness of clinical interventions is often assessed using current care as comparator. However, evidence suggests practice variation in stroke imaging across countries. For the purpose of feedi...
A systematic review of health economic models and utility estimation methods in schizophrenia [0.03%]
系统性回顾：精神分裂症的卫生经济学模型和效用评估方法
Bertalan Németh,Ahmad Fasseeh,Anett Molnár et al.
Bertalan Németh et al.
Introduction: There is a growing need for economic evaluations describing the disease course, as well as the costs and clinical outcomes related to the treatment of schizophrenia. ...
Most important barriers and facilitators of HTA usage in decision-making in Europe [0.03%]
欧洲卫生技术评估使用的重要障碍和促进因素：决策中的HTA使用的最重要障碍和促进因素是什么？
K L Cheung,S M A A Evers,H De Vries et al.
K L Cheung et al.
Background: To enhance usage of health technology assessment (HTA) in decision-making, it is important to prioritise important barriers and facilitators to the uptake of HTA. This study aims to quantify and compare the re...
Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry [0.03%]
制药行业并购交易估值及战略导向之批判分析
Raphaela Marie Louisa Dierks,Olivier Bruyère,Jean-Yves Reginster
Raphaela Marie Louisa Dierks
Introduction: The pharmaceutical industry is undergoing major shifts due to changing macro and micro factors. As the industry is highly capital intensive and patents are expiring, the outlook is on generating inorganic gr...
Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models [0.03%]
慢性心力衰竭管理的早期预警系统的系统文献综述：成本效益模型
Fernando Albuquerque De Almeida,Maiwenn Al,Ron Koymans et al.
Fernando Albuquerque De Almeida et al.
Introduction: Describing the general and methodological characteristics of decision-analytical models used in the economic evaluation of early warning systems for the management of chronic heart failure patients and perfo...
Management of dental caries among children: a look at the cost-effectiveness [0.03%]
儿童龋齿的防治：成本效益分析 взгляд на(cost-效益分析)儿童龋齿的管理
Nathalia Miranda Ladewig,Lucila Basto Camargo,Tamara Kerber Tedesco et al.
Nathalia Miranda Ladewig et al.
Introduction: Dental caries is the most prevalent non-communicative disease worldwide. Although the etiological factors are well known for years, reducing the number of decayed and missing teeth in children still remains ...
Using multi-criteria decision analysis to appraise orphan drugs: a systematic review [0.03%]
评价孤儿药的多准则决策分析法：系统综述
Carlotta Friedmann,Pierre Levy,Paul Hensel et al.
Carlotta Friedmann et al.
Introduction: Multi-criteria decision analysis (MCDA) could potentially solve current methodological difficulties in the appraisal of orphan drugs. Areas ...
Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain [0.03%]
西班牙中重度溃疡性结肠炎患者使用英夫利昔单抗、阿达木单抗、戈利木单抗和维多珠单抗的药物经济学分析研究
Cristina Trigo-Vicente,Vicente Gimeno-Ballester,Raquel Montoiro-Allué et al.
Cristina Trigo-Vicente et al.
Objectives: Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. ...